

Emil R Bulatov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8598792/publications.pdf>

Version: 2024-02-01

26
papers

787
citations

471061

17
h-index

610482

24
g-index

26
all docs

26
docs citations

26
times ranked

1312
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. <i>Biochemical Journal</i> , 2015, 467, 365-386.	1.7	168
2	The biological basis and clinical symptoms of CAR-T therapy-associated toxicities. <i>Cell Death and Disease</i> , 2018, 9, 897.	2.7	90
3	Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. <i>Biomedicines</i> , 2021, 9, 59.	1.4	60
4	Adoptive Immunotherapy beyond CAR T-Cells. <i>Cancers</i> , 2021, 13, 743.	1.7	57
5	Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. <i>Cancers</i> , 2020, 12, 125.	1.7	50
6	Isatin-Schiff base-copper (II) complex induces cell death in p53-positive tumors. <i>Cell Death Discovery</i> , 2018, 4, 103.	2.0	41
7	Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?. <i>Genes</i> , 2020, 11, 704.	1.0	31
8	Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 1460.	1.3	30
9	Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 707734.	2.2	30
10	Biophysical Studies on Interactions and Assembly of Full-size E3 Ubiquitin Ligase. <i>Journal of Biological Chemistry</i> , 2015, 290, 4178-4191.	1.6	24
11	Ubiquitin-Proteasome System: Promising Therapeutic Targets in Autoimmune and Neurodegenerative Diseases. <i>BioNanoScience</i> , 2016, 6, 341-344.	1.5	24
12	Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets. <i>Frontiers in Pharmacology</i> , 2018, 9, 450.	1.6	23
13	Knowns and Unknowns about CAR-T Cell Dysfunction. <i>Cancers</i> , 2022, 14, 1078.	1.7	23
14	Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. <i>Immunology Letters</i> , 2018, 202, 44-51.	1.1	20
15	Novel Isatin-based activator of p53 transcriptional functions in tumor cells. <i>Molecular Biology Research Communications</i> , 2019, 8, 119-128.	0.2	19
16	Effect of size and protein environment on electrochemical properties of gold nanoparticles on carbon electrodes. <i>Bioelectrochemistry</i> , 2009, 77, 37-42.	2.4	18
17	Binding and purification of plasmid DNA using multi-layered carbon nanotubes. <i>Journal of Biotechnology</i> , 2011, 152, 102-107.	1.9	18
18	Novel approaches for the rational design of PROTAC linkers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, 381-390.	0.5	17

#	ARTICLE	IF	CITATIONS
19	Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases. PLoS ONE, 2015, 10, e0131218.	1.1	16
20	Endonuclease from Gram-Negative Bacteria <i>Serratia marcescens</i> Is as Effective as Pulmozyme in the Hydrolysis of DNA in Sputum. Frontiers in Pharmacology, 2018, 9, 114.	1.6	13
21	Design, synthesis and biological evaluation of 2-quinolyl-1,3-tropolone derivatives as new anti-cancer agents. RSC Advances, 2021, 11, 4555-4571.	1.7	11
22	Granulocyte-Macrophage Colony-Stimulating Factor and CAR-T Technology for Solid Tumors in Experiment. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2020, 13, 115-122.	0.1	2
23	A One-Step Protocol for Chromatographic Purification of Non-recombinant Exogenous Bacterial Enzyme: Nuclease of <i>Serratia marcescens</i> . BioNanoScience, 2016, 6, 335-337.	1.5	1
24	The Effect of Macrophage Polarization on Cytokine Release in CAR-T Antitumor Response. Blood, 2020, 136, 22-22.	0.6	1
25	Expression of mutant p53 affects cancer cell sensitivity to topotecan. Annals of Oncology, 2019, 30, v803.	0.6	0
26	Screening for Immunosuppressive Genes Responsible for Resistance Towards CAR-T Cell Therapy in Cancer Cells. Blood, 2018, 132, 4965-4965.	0.6	0